{
    "hands_on_practices": [
        {
            "introduction": "The transmission route of a virus is fundamentally linked to its ability to survive in different environments. Within the Picornaviridae family, this is starkly illustrated by comparing enteroviruses like poliovirus, which travel the fecal-oral route, with rhinoviruses, which spread via respiratory droplets. This practice explores the biophysical basis for this difference—acid stability—by asking you to calculate and contrast the survival probabilities of these viruses in a low pH environment, modeling their decay using first-order kinetics. By quantifying this crucial property, you will gain a deeper appreciation for how the structural characteristics of a virion dictate its pathogenesis and epidemiology .",
            "id": "4661931",
            "problem": "In the Picornaviridae family, enteroviruses such as poliovirus and coxsackieviruses are known for relative acid stability, while rhinoviruses are acid labile. Consider an experimental setup in which two virus preparations are held at constant $\\text{pH}\\,3$ and $37^{\\circ}\\mathrm{C}$ for $24$ hours in a buffered solution with no protective proteins or cellular debris, such that the inactivation of infectious particles follows first-order kinetics (constant hazard) over time. Assume that the survival probability at time $t$ is equal to the fraction of infectious particles remaining, under the assumption of independent and identically distributed inactivation events.\n\nYou are given the following empirically measured half-lives at $\\text{pH}\\,3$:\n- Enterovirus preparation half-life: $6$ hours.\n- Rhinovirus preparation half-life: $0.5$ hours.\n\nStarting from the core definitions of first-order decay and half-life, derive the survival probability function and use it to calculate the survival probability after $24$ hours for each preparation at $\\text{pH}\\,3$. Express each survival probability as a decimal fraction and round your results to four significant figures. Report your final result as a row matrix with the enterovirus value first and the rhinovirus value second.",
            "solution": "The experimental conditions specify constant $\\text{pH}$ and temperature, with no protective effects, and the observation that the inactivation of infectious particles follows first-order kinetics. In first-order decay, the number of surviving infectious particles $N(t)$ at time $t$ is given by\n$$\nN(t) = N_{0}\\,\\exp(-k t),\n$$\nwhere $N_{0}$ is the initial number of infectious particles and $k$ is the first-order rate constant (hazard). The survival probability $S(t)$ is the fraction of infectious particles that remain infectious at time $t$, which under independence is\n$$\nS(t) = \\frac{N(t)}{N_{0}} = \\exp(-k t).\n$$\n\nThe half-life $t_{1/2}$ is defined as the time at which half the infectious particles remain, so by definition\n$$\nN(t_{1/2}) = \\frac{N_{0}}{2}.\n$$\nSubstituting the first-order decay model,\n$$\nN_{0}\\,\\exp(-k t_{1/2}) = \\frac{N_{0}}{2} \\quad \\Rightarrow \\quad \\exp(-k t_{1/2}) = \\frac{1}{2}.\n$$\nTaking the natural logarithm,\n$$\n-k t_{1/2} = \\ln\\!\\left(\\frac{1}{2}\\right) = -\\ln(2) \\quad \\Rightarrow \\quad k = \\frac{\\ln(2)}{t_{1/2}}.\n$$\nSubstituting this relation into the survival probability gives\n$$\nS(t) = \\exp\\!\\left(-\\frac{\\ln(2)}{t_{1/2}}\\,t\\right) = \\exp\\!\\left(-\\ln(2)\\,\\frac{t}{t_{1/2}}\\right) = 2^{-t/t_{1/2}}.\n$$\n\nWe now compute $S(t)$ at $t = 24$ hours for each preparation.\n\n1. Enterovirus ($t_{1/2} = 6$ hours):\n$$\nS_{\\text{enterovirus}}(24) = 2^{-24/6} = 2^{-4} = \\frac{1}{16} = 0.0625.\n$$\nRounded to four significant figures, this is $0.0625$ (already exact to four significant figures).\n\n2. Rhinovirus ($t_{1/2} = 0.5$ hours):\n$$\nS_{\\text{rhinovirus}}(24) = 2^{-24/0.5} = 2^{-48}.\n$$\nTo express as a decimal and round to four significant figures, we evaluate $2^{-48}$:\n$$\n2^{-48} \\approx 3.552713678800501 \\times 10^{-15}.\n$$\nRounded to four significant figures,\n$$\nS_{\\text{rhinovirus}}(24) \\approx 3.553 \\times 10^{-15}.\n$$\n\nThese results reflect the underlying biochemical differences in acid stability within Picornaviridae: the enterovirus retains a small but non-negligible fraction of infectivity after $24$ hours at $\\text{pH}\\,3$, whereas the rhinovirus is effectively inactivated, with survival probability orders of magnitude lower. The contrast can be quantified by the ratio\n$$\n\\frac{S_{\\text{enterovirus}}(24)}{S_{\\text{rhinovirus}}(24)} = \\frac{2^{-4}}{2^{-48}} = 2^{44},\n$$\nillustrating a difference of approximately $1.76 \\times 10^{13}$ in survival fraction under these conditions.\n\nPer the instructions, the final reported values are the survival probabilities rounded to four significant figures, in the order enterovirus then rhinovirus.",
            "answer": "$$\\boxed{\\begin{pmatrix} 0.0625 & 3.553 \\times 10^{-15} \\end{pmatrix}}$$"
        },
        {
            "introduction": "A defining feature of RNA viruses, including picornaviruses, is their high mutation rate, largely due to the lack of proofreading activity in their RNA-dependent RNA polymerase (RdRp). This genetic instability is a double-edged sword: it fuels rapid evolution and adaptation, but it also generates a substantial number of non-viable offspring. This exercise provides a quantitative framework to explore this balance by modeling the accumulation of lethal mutations during a single replication cycle. By calculating the fraction of non-viable progeny, you will connect the molecular error rate of the polymerase to the overall fitness and survival of the viral population .",
            "id": "4661999",
            "problem": "A picornavirus such as poliovirus, rhinovirus, or coxsackievirus has a single-stranded positive-sense ribonucleic acid (RNA) genome. Consider a replication cycle in which the RNA-dependent RNA polymerase (RdRp) makes independent per-base copying errors with probability $p$ on a genome of length $L$ nucleotides (nt). Errors are rare and independent across positions. Empirical evidence supports modeling the total number of replication errors per genome per cycle as a Poisson process under these conditions. Further suppose that each individual mutation is independently lethal with probability $f_{\\ell}$, meaning it renders the progeny genome nonviable.\n\nGiven $L = 7{,}500$ nt, $p = 1 \\times 10^{-4}$ per base per replication cycle, and $f_{\\ell} = 0.3$, derive from first principles an expression for the fraction of progeny genomes that are rendered nonviable by at least one lethal mutation in a single replication cycle. Then evaluate the expression numerically with the provided parameters. Round your final answer to four significant figures and express it as a unitless decimal fraction.",
            "solution": "The problem is evaluated to be valid as it is scientifically grounded in the principles of virology and population genetics, is well-posed with sufficient information, and is stated objectively.\n\nThe problem asks for the fraction of progeny genomes that are rendered nonviable by at least one lethal mutation in a single replication cycle. We can derive this from first principles by modeling the underlying stochastic processes.\n\nFirst, we model the number of mutations per genome per replication cycle. The genome has a length of $L$ nucleotides. The RNA-dependent RNA polymerase (RdRp) makes a copying error at any given nucleotide with a probability $p$. Since the errors are assumed to be independent across positions, we can model the number of mutations, $N$, in a single replication cycle as a binomial random variable:\n$$N \\sim \\text{Binomial}(L, p)$$\nThe problem statement notes that errors are rare ($p$ is small) and the genome is long ($L$ is large). Under these conditions, the binomial distribution can be accurately approximated by a Poisson distribution with the same mean. The mean of the binomial distribution is $\\lambda = L p$.\nTherefore, the probability of having exactly $k$ mutations in a newly synthesized genome is given by the Poisson probability mass function:\n$$P(N=k) = \\frac{\\lambda^k \\exp(-\\lambda)}{k!}, \\quad \\text{where } \\lambda = L p$$\n\nNext, we consider the lethality of these mutations. Each mutation is independently lethal with a probability $f_{\\ell}$. A progeny genome is nonviable if it contains at least one lethal mutation. It is easier to first calculate the probability of the complementary event: that a progeny genome is viable. A genome is viable only if it contains zero lethal mutations.\n\nLet's consider a genome that has exactly $k$ mutations. For this genome to be viable, all $k$ of its mutations must be non-lethal. The probability that a single mutation is non-lethal is $(1 - f_{\\ell})$. Since the lethality of each mutation is independent, the probability that all $k$ mutations are non-lethal, given that there are $k$ mutations, is:\n$$P(\\text{viable} | N=k) = (1 - f_{\\ell})^k$$\nConsequently, the probability that a genome with $k$ mutations is nonviable is:\n$$P(\\text{nonviable} | N=k) = 1 - P(\\text{viable} | N=k) = 1 - (1 - f_{\\ell})^k$$\n\nTo find the total fraction of nonviable progeny genomes, $F_{nv}$, we must sum this conditional probability over all possible numbers of mutations $k$, weighted by the probability of having $k$ mutations, $P(N=k)$. This is an application of the law of total probability:\n$$F_{nv} = P(\\text{nonviable}) = \\sum_{k=0}^{\\infty} P(\\text{nonviable} | N=k) P(N=k)$$\nSubstituting the expressions we derived:\n$$F_{nv} = \\sum_{k=0}^{\\infty} \\left[1 - (1 - f_{\\ell})^k\\right] \\frac{\\lambda^k \\exp(-\\lambda)}{k!}$$\nWe can split the summation into two parts:\n$$F_{nv} = \\sum_{k=0}^{\\infty} \\frac{\\lambda^k \\exp(-\\lambda)}{k!} - \\sum_{k=0}^{\\infty} (1 - f_{\\ell})^k \\frac{\\lambda^k \\exp(-\\lambda)}{k!}$$\nThe first term is the sum of all probabilities of the Poisson distribution, which equals $1$:\n$$\\sum_{k=0}^{\\infty} P(N=k) = \\exp(-\\lambda) \\sum_{k=0}^{\\infty} \\frac{\\lambda^k}{k!} = \\exp(-\\lambda) \\exp(\\lambda) = 1$$\nThe second term can be rearranged by combining the powers of $k$ and factoring out the constant $\\exp(-\\lambda)$:\n$$\\exp(-\\lambda) \\sum_{k=0}^{\\infty} \\frac{[\\lambda(1 - f_{\\ell})]^k}{k!}$$\nThis sum is the Taylor series expansion for the exponential function $\\exp(x)$ with $x = \\lambda(1 - f_{\\ell})$. Thus, the second term simplifies to:\n$$\\exp(-\\lambda) \\exp(\\lambda(1 - f_{\\ell})) = \\exp(-\\lambda + \\lambda - \\lambda f_{\\ell}) = \\exp(-\\lambda f_{\\ell})$$\nCombining the results for the two terms, we arrive at the final expression:\n$$F_{nv} = 1 - \\exp(-\\lambda f_{\\ell})$$\n\nAn alternative, more direct derivation uses the property of \"thinning\" a Poisson process. If events in a Poisson process with rate $\\lambda$ are independently selected with probability $f_{\\ell}$, the resulting selected events also form a Poisson process with rate $\\lambda_{\\ell} = \\lambda f_{\\ell}$. In our case, the total number of mutations $N$ is Poisson distributed with mean $\\lambda$. Each mutation is independently a \"lethal\" event with probability $f_{\\ell}$. Therefore, the number of lethal mutations, $N_{\\ell}$, is also Poisson distributed with mean $\\lambda_{\\ell} = \\lambda f_{\\ell}$.\nA genome is nonviable if the number of lethal mutations is one or more, i.e., $N_{\\ell} \\ge 1$. The probability of this event is:\n$$F_{nv} = P(N_{\\ell} \\ge 1) = 1 - P(N_{\\ell} = 0)$$\nUsing the Poisson probability mass function for $N_{\\ell}$ with mean $\\lambda_{\\ell}$:\n$$P(N_{\\ell} = 0) = \\frac{\\lambda_{\\ell}^0 \\exp(-\\lambda_{\\ell})}{0!} = \\exp(-\\lambda_{\\ell})$$\nSubstituting back, we get the same expression:\n$$F_{nv} = 1 - \\exp(-\\lambda_{\\ell}) = 1 - \\exp(-\\lambda f_{\\ell})$$\n\nNow we substitute the given numerical values:\nGenome length: $L = 7,500$ nt\nPer-base error probability: $p = 1 \\times 10^{-4}$ per base per cycle\nLethal fraction of mutations: $f_{\\ell} = 0.3$\n\nFirst, calculate the mean number of mutations per genome, $\\lambda$:\n$$\\lambda = L p = 7500 \\times (1 \\times 10^{-4}) = 0.75$$\nThis is the average number of errors per genome produced in one replication cycle.\n\nNext, we calculate the mean number of lethal mutations per genome, $\\lambda_{\\ell}$:\n$$\\lambda_{\\ell} = \\lambda f_{\\ell} = 0.75 \\times 0.3 = 0.225$$\n\nFinally, we calculate the fraction of nonviable progeny, $F_{nv}$:\n$$F_{nv} = 1 - \\exp(-\\lambda_{\\ell}) = 1 - \\exp(-0.225)$$\nUsing a calculator:\n$$\\exp(-0.225) \\approx 0.798516168$$\n$$F_{nv} \\approx 1 - 0.798516168 = 0.201483832$$\nThe problem requires the answer to be rounded to four significant figures. The first four significant figures are $2$, $0$, $1$, $4$. The fifth significant digit is $8$, so we round up the fourth digit.\n$$F_{nv} \\approx 0.2015$$\nThus, approximately $20.15\\%$ of the progeny genomes are rendered nonviable due to lethal mutations in a single replication cycle.",
            "answer": "$$\\boxed{0.2015}$$"
        },
        {
            "introduction": "Understanding the mechanism of vaccine-induced immunity is critical to designing effective public health strategies. For poliovirus, the choice between the oral poliovirus vaccine (OPV) and the inactivated poliovirus vaccine (IPV) hinges on the distinct types of immunity they elicit—mucosal versus systemic. This practice challenges you to apply these immunological principles within a quantitative epidemiological model to predict the impact of each vaccine on community transmission. By calculating the effective reproduction number ($R_e$), you will see how different immune responses translate directly into different public health outcomes, highlighting why mucosal immunity is key to interrupting fecal-oral transmission .",
            "id": "4662023",
            "problem": "A health department must choose between Oral Poliovirus Vaccine (OPV) and Inactivated Poliovirus Vaccine (IPV) to interrupt fecal-oral transmission of poliovirus in a densely populated district. Use the following foundational facts and definitions to construct and evaluate a causal model:\n\n- Poliovirus is transmitted via the fecal-oral route; transmission requires intestinal infection, replication, and shedding.\n- Secretory Immunoglobulin A (IgA) at mucosal surfaces can neutralize virus in the intestinal lumen and limit replication and shedding.\n- Systemic Immunoglobulin G (IgG) in serum neutralizes virus in blood, limiting viremia and neuroinvasion but has limited access to the intestinal lumen.\n- The Effective Reproduction Number ($R_e$) can be decomposed as $$R_e = c \\times p_t \\times D,$$ where $c$ is the contact rate relevant to fecal-oral exposure, $p_t$ is the per-contact transmission probability (driven by intestinal susceptibility and shedding), and $D$ is the duration of infectiousness (driven by duration and magnitude of shedding). The Basic Reproduction Number ($R_0$) in an unvaccinated population equals $R_e$ under baseline conditions.\n\nIn this district, prior to vaccination, $R_0 = 6$. After immunization:\n\n- In OPV recipients, mucosal IgA is measured in stool and is observed to reduce per-contact transmission probability by approximately $70\\%$ (that is, multiply $p_t$ by $0.3$) and to shorten the infectious period by approximately $50\\%$ (that is, multiply $D$ by $0.5$), with no change in $c$.\n- In IPV recipients, high serum neutralizing IgG reduces the risk of paralytic disease by approximately $99\\%$ (reflecting blockade of viremia and neuroinvasion), but stool studies show only approximately $10\\%$ reduction in fecal shedding parameters (that is, multiply $p_t$ by $0.9$; assume no change in $D$ and no change in $c$).\n\nWhich option most accurately specifies the causal pathway that links the type of immunity induced by each vaccine to its effect on fecal-oral transmission and correctly predicts whether transmission will be interrupted in this setting?\n\nA. OPV induces intestinal secretory IgA that neutralizes poliovirus in the gut lumen and limits intestinal replication, thereby decreasing both per-contact transmission probability and duration of infectiousness. With $R_0 = 6$, OPV yields $$R_e^{\\mathrm{OPV}} = 6 \\times 0.3 \\times 0.5 = 0.9,$$ so $R_e^{\\mathrm{OPV}} < 1$, predicting interruption of transmission. IPV induces systemic IgG that blocks viremia and paralytic disease but leaves intestinal replication largely intact; with $p_t$ multiplied by $0.9$ and no change in $D$, $$R_e^{\\mathrm{IPV}} = 6 \\times 0.9 \\times 1.0 = 5.4,$$ so $R_e^{\\mathrm{IPV}} > 1$, predicting ongoing transmission.\n\nB. IPV causes a larger reduction in fecal-oral transmission than OPV because systemic IgG abundantly transudates into the gut lumen to neutralize poliovirus before intestinal attachment, sharply reducing per-contact transmission probability; OPV mainly prevents disease severity without changing transmission. Thus, $R_e^{\\mathrm{IPV}}$ drops below $1$, while $R_e^{\\mathrm{OPV}}$ remains above $1$.\n\nC. OPV primarily reduces clinical disease without altering mucosal replication, but by keeping recipients asymptomatic it increases social mixing and contact rate; suppose $c$ increases by $50\\%$ (multiply $c$ by $1.5$), offsetting any small changes in $p_t$ or $D$, so $R_e^{\\mathrm{OPV}}$ remains above $1$. IPV, by reducing symptoms even more, has a similar effect on $c$, so neither vaccine interrupts transmission.\n\nD. Both OPV and IPV act mainly through T-cell cytotoxicity in neurons to prevent paralysis, with negligible effects on intestinal replication or shedding; therefore $p_t$ and $D$ are essentially unchanged under both vaccines, and $R_e$ is unaltered for transmission dynamics in the community.",
            "solution": "The user has requested a critical validation of the problem statement, followed by a detailed solution and evaluation of options if the problem is deemed valid.\n\n### Step 1: Extract Givens\n\nThe problem provides the following information and definitions:\n1.  **Transmission Route:** Poliovirus is transmitted via the fecal-oral route. Transmission requires intestinal infection, replication, and shedding.\n2.  **Mucosal Immunity:** Secretory Immunoglobulin A (IgA) at mucosal surfaces neutralizes virus in the intestinal lumen, limiting replication and shedding.\n3.  **Systemic Immunity:** Systemic Immunoglobulin G (IgG) in serum neutralizes virus in blood, limiting viremia and neuroinvasion, but has limited access to the intestinal lumen.\n4.  **Reproduction Number Model:** The Effective Reproduction Number ($R_e$) is given by the equation $$R_e = c \\times p_t \\times D$$, where:\n    *   $c$ is the contact rate.\n    *   $p_t$ is the per-contact transmission probability.\n    *   $D$ is the duration of infectiousness.\n5.  **Baseline Condition:** The Basic Reproduction Number ($R_0$) in an unvaccinated population is given as $R_0 = 6$.\n6.  **Oral Poliovirus Vaccine (OPV) Effects:**\n    *   Induces mucosal IgA.\n    *   Reduces per-contact transmission probability by $70\\%$, which corresponds to a multiplication factor of $0.3$ for $p_t$.\n    *   Shortens the infectious period by $50\\%$, which corresponds to a multiplication factor of $0.5$ for $D$.\n    *   The contact rate $c$ is unchanged.\n7.  **Inactivated Poliovirus Vaccine (IPV) Effects:**\n    *   Induces high serum neutralizing IgG.\n    *   Reduces the risk of paralytic disease by $99\\%$.\n    *   Reduces fecal shedding parameters by $10\\%$, specified as multiplying $p_t$ by a factor of $0.9$.\n    *   The duration of infectiousness $D$ is unchanged.\n    *   The contact rate $c$ is unchanged.\n8.  **Objective:** The goal is to identify the option that correctly describes the causal pathway for each vaccine and accurately predicts the interruption of transmission, which occurs when $R_e < 1$.\n\n### Step 2: Validate Using Extracted Givens\n\nThe problem statement is evaluated against standard criteria for validity.\n\n*   **Scientifically Grounded:** The problem is firmly based on established principles of virology and immunology concerning poliovirus. The distinction between the mucosal immunity (IgA) induced by the live-attenuated OPV and the systemic immunity (IgG) induced by the inactivated IPV is a cornerstone of polio vaccinology. The described effects on intestinal replication versus viremia are scientifically accurate.\n*   **Well-Posed:** The problem is well-posed. It provides a clear mathematical model ($R_e = c \\times p_t \\times D$), a baseline value ($R_0 = 6$), and specific, quantitative effects for each intervention on the model's parameters. This allows for the calculation of a unique solution for $R_e$ for both OPV and IPV.\n*   **Objective:** The problem is stated in objective, quantitative terms, free from subjective language or opinion.\n*   **Completeness and Consistency:** The problem is self-contained and internally consistent. It provides all necessary data to perform the required calculations. The effects of each vaccine are explicitly defined, avoiding ambiguity. For instance, it clarifies that the \"reduction in fecal shedding parameters\" for IPV means to multiply $p_t$ by $0.9$ and explicitly states that $c$ and $D$ are unchanged in this case. There are no contradictions.\n\n### Step 3: Verdict and Action\n\nThe problem statement is **valid**. It is a well-constructed problem in quantitative epidemiology based on sound immunological principles. The solution process may proceed.\n\n### Derivation of Solution\n\nThe condition for interrupting transmission is that the effective reproduction number, $R_e$, must be less than $1$. We are given the baseline reproduction number, $R_0 = 6$. We can express the post-vaccination $R_e$ in terms of $R_0$.\nThe baseline is $R_0 = c_{\\text{base}} \\times p_{t, \\text{base}} \\times D_{\\text{base}} = 6$.\n\n**Analysis of Oral Poliovirus Vaccine (OPV):**\nThe problem states that for OPV recipients:\n*   $c$ is unchanged: $c_{\\text{OPV}} = c_{\\text{base}}$.\n*   $p_t$ is reduced by $70\\%$: $p_{t, \\text{OPV}} = (1 - 0.70) \\times p_{t, \\text{base}} = 0.3 \\times p_{t, \\text{base}}$.\n*   $D$ is reduced by $50\\%$: $D_{\\text{OPV}} = (1 - 0.50) \\times D_{\\text{base}} = 0.5 \\times D_{\\text{base}}$.\n\nThe effective reproduction number in a fully OPV-vaccinated population, $R_e^{\\mathrm{OPV}}$, is:\n$$R_e^{\\mathrm{OPV}} = c_{\\text{OPV}} \\times p_{t, \\text{OPV}} \\times D_{\\text{OPV}}$$\n$$R_e^{\\mathrm{OPV}} = c_{\\text{base}} \\times (0.3 \\times p_{t, \\text{base}}) \\times (0.5 \\times D_{\\text{base}})$$\n$$R_e^{\\mathrm{OPV}} = (0.3 \\times 0.5) \\times (c_{\\text{base}} \\times p_{t, \\text{base}} \\times D_{\\text{base}})$$\n$$R_e^{\\mathrm{OPV}} = 0.15 \\times R_0$$\n$$R_e^{\\mathrm{OPV}} = 0.15 \\times 6 = 0.9$$\nSince $R_e^{\\mathrm{OPV}} = 0.9 < 1$, the model predicts that OPV will interrupt fecal-oral transmission. This effect is mediated by a strong reduction in both the probability and duration of infectious shedding, consistent with the induction of robust mucosal IgA.\n\n**Analysis of Inactivated Poliovirus Vaccine (IPV):**\nThe problem states that for IPV recipients:\n*   $c$ is unchanged: $c_{\\text{IPV}} = c_{\\text{base}}$.\n*   $p_t$ is reduced by $10\\%$: $p_{t, \\text{IPV}} = (1 - 0.10) \\times p_{t, \\text{base}} = 0.9 \\times p_{t, \\text{base}}$.\n*   $D$ is unchanged: $D_{\\text{IPV}} = D_{\\text{base}}$.\n\nThe effective reproduction number in a fully IPV-vaccinated population, $R_e^{\\mathrm{IPV}}$, is:\n$$R_e^{\\mathrm{IPV}} = c_{\\text{IPV}} \\times p_{t, \\text{IPV}} \\times D_{\\text{IPV}}$$\n$$R_e^{\\mathrm{IPV}} = c_{\\text{base}} \\times (0.9 \\times p_{t, \\text{base}}) \\times D_{\\text{base}}$$\n$$R_e^{\\mathrm{IPV}} = 0.9 \\times (c_{\\text{base}} \\times p_{t, \\text{base}} \\times D_{\\text{base}})$$\n$$R_e^{\\mathrm{IPV}} = 0.9 \\times R_0$$\n$$R_e^{\\mathrm{IPV}} = 0.9 \\times 6 = 5.4$$\nSince $R_e^{\\mathrm{IPV}} = 5.4 > 1$, the model predicts that IPV will *not* interrupt fecal-oral transmission. While it significantly reduces the incidence of paralytic disease (by $99\\%$) via systemic IgG, its effect on intestinal replication and shedding is minimal, consistent with IgG's limited access to the gut lumen.\n\n### Option-by-Option Analysis\n\n**A. OPV induces intestinal secretory IgA that neutralizes poliovirus in the gut lumen and limits intestinal replication, thereby decreasing both per-contact transmission probability and duration of infectiousness. With $R_0 = 6$, OPV yields $$R_e^{\\mathrm{OPV}} = 6 \\times 0.3 \\times 0.5 = 0.9,$$ so $R_e^{\\mathrm{OPV}} < 1$, predicting interruption of transmission. IPV induces systemic IgG that blocks viremia and paralytic disease but leaves intestinal replication largely intact; with $p_t$ multiplied by $0.9$ and no change in $D$, $$R_e^{\\mathrm{IPV}} = 6 \\times 0.9 \\times 1.0 = 5.4,$$ so $R_e^{\\mathrm{IPV}} > 1$, predicting ongoing transmission.**\n*   **Justification:** This option correctly describes the immunological mechanisms for both OPV (mucosal IgA) and IPV (systemic IgG) as given in the problem's foundational facts. The calculations for both $R_e^{\\mathrm{OPV}}$ ($0.9$) and $R_e^{\\mathrm{IPV}}$ ($5.4$) are arithmetically correct and match the derivation above. The conclusions drawn from these calculations—that OPV interrupts transmission ($R_e < 1$) while IPV does not ($R_e > 1$)—are also correct.\n*   **Verdict:** **Correct**.\n\n**B. IPV causes a larger reduction in fecal-oral transmission than OPV because systemic IgG abundantly transudates into the gut lumen to neutralize poliovirus before intestinal attachment, sharply reducing per-contact transmission probability; OPV mainly prevents disease severity without changing transmission. Thus, $R_e^{\\mathrm{IPV}}$ drops below $1$, while $R_e^{\\mathrm{OPV}}$ remains above $1$.**\n*   **Justification:** This option makes several claims that contradict the problem statement. It claims IgG \"abundantly transudates into the gut,\" which contradicts the given fact that IgG has \"limited access to the intestinal lumen.\" It claims IPV causes a larger reduction in transmission than OPV, which contradicts the provided quantitative data ($p_t$ factor of $0.9$ for IPV vs. factors of $0.3$ and $0.5$ for OPV). Consequently, its conclusion that $R_e^{\\mathrm{IPV}} < 1$ and $R_e^{\\mathrm{OPV}} > 1$ is the opposite of the calculated result.\n*   **Verdict:** **Incorrect**.\n\n**C. OPV primarily reduces clinical disease without altering mucosal replication, but by keeping recipients asymptomatic it increases social mixing and contact rate; suppose $c$ increases by $50\\%$ (multiply $c$ by $1.5$), offsetting any small changes in $p_t$ or $D$, so $R_e^{\\mathrm{OPV}}$ remains above $1$. IPV, by reducing symptoms even more, has a similar effect on $c$, so neither vaccine interrupts transmission.**\n*   **Justification:** This option introduces an assumption that the contact rate $c$ increases. This directly contradicts the problem statement, which explicitly says \"with no change in $c$\" for both OPV and IPV. Furthermore, it incorrectly claims OPV does not alter mucosal replication, which is contrary to the given data (reductions in $p_t$ and $D$).\n*   **Verdict:** **Incorrect**.\n\n**D. Both OPV and IPV act mainly through T-cell cytotoxicity in neurons to prevent paralysis, with negligible effects on intestinal replication or shedding; therefore $p_t$ and $D$ are essentially unchanged under both vaccines, and $R_e$ is unaltered for transmission dynamics in the community.**\n*   **Justification:** This option introduces a mechanism (T-cell cytotoxicity in neurons) not mentioned anywhere in the problem's foundational facts, which focus on antibody-mediated immunity (IgA and IgG). It falsely claims that the effects on intestinal replication and shedding are \"negligible\" and that $p_t$ and $D$ are \"essentially unchanged.\" This is in direct contradiction with the explicit quantitative data provided for both vaccines.\n*   **Verdict:** **Incorrect**.",
            "answer": "$$\\boxed{A}$$"
        }
    ]
}